Fluorescence Sensor Probe for Transcutaneous Glucose Sensing

用于经皮血糖传感的荧光传感器探头

• 批准号: 7460781
• 负责人: Ralph Ballerstadt
• 金额: $ 37.27万
• 依托单位: BIOTEX, INC.
• 依托单位国家: 美国
• 财政年份: 2004
• 资助国家: 美国
• 起止时间: 2004-05-01 至 2010-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7460781
• 关键词: Address; Adolescent; Affinity; Algorithms; Animal Experiments; Biocompatible; Biomimetics; Blindness; Blood Glucose; Caring; Cause of Death; Cell Adhesion; Cell-Matrix Junction; Chemicals; Chronic; Collaborations; Concanavalin A; Condition; Data; Development; Devices; Diabetes Mellitus; Disease; Disruption; Dose; Drug Formulations; Effectiveness; Endocrinologist; Engineering; Ensure; Fiber; Fluorescence; Freeze Drying; Glucose; Goals; Grant; Health; Health Status; Histology; Human; Immune response; In Vitro; Insulin; Insulin Infusion Systems; Insulin-Dependent Diabetes Mellitus; Intervention; Invasive; Kidney Failure; Laboratories; Life; Medical; Methodology; Methods; Natural regeneration; Needles; Optics; Peptides; Performance; Phase; Phase II Clinical Trials; Polysaccharides; Preparation; Protocols documentation; Public Health; Radiation; Radiation Dosage; Rattus; Reading; Research; Research Personnel; Research Project Grants; Retrieval; Safety; Scientist; Signal Transduction; Skin Tissue; Societies; Sterility; Sterilization for infection control; Surface; Techniques; Technology; Testing; Therapeutic; Therapeutic Studies; Time; Tissue Engineering; Tissues; Toxicology; United States; United States Food and Drug Administration; Vacuum; Vascularization; Viola; Week; Work; Wound Healing; acetylcellulose; base; biomaterial compatibility; blood glucose regulation; capsule; concept; cost; day; design; diabetes mellitus therapy; diabetic; glucose monitor; glucose sensor; human study; implantation; implanted sensor; improved; in vivo; irradiation; miniaturize; monitoring device; mortality; prevent; radiation effect; response; seal; sensor

DESCRIPTION (provided by applicant): There is an urgent need for a long-term in vivo glucose-monitoring device for diabetes therapy. Diabetes is currently believed to afflict over 100 million people worldwide and nearly 18 million in the United States. In the U.S. this disorder, along with its associated complications, is ranked as the seventh leading cause of death. Research indicates that these long-term complications can be minimized in diabetics if blood glucose levels are maintained as near normal levels (60-110 mg/dL) as possible, so called "tight" glucose control. The integration of continuous glucose monitor readings into an automatic insulin pump control algorithm may substantially increase both the safety and effectiveness of insulin therapy in diabetics. BioTex, Inc. has developed a superior concept of a minimally invasive fluorescence affinity glucose sensor which is one of the most promising long-term glucose-sensing technologies currently being pursued for application in diabetes research and therapy. The ultimate objective of the proposed research is to advance our fluorescence sensor, in preparation for preliminary human trials subsequent to completion of Phase II. To accomplish this challenging goal, we will concentrate our efforts in Phase II on the following tasks: I. BioTex chemists and collaborators Dr.Stephen Massia and Dr.Fred Clubb will design, test, and optimize suitable chemical protocols for covalent attachment of biomimetic layer(s) on outer sensor surface for improved biocompatibility and, hence, extended in vivo sensor functionality in rats. II. BioTex chemists and engineers will perform studies to optimize a pre-sterilization formulation protocol of sensor by freeze-drying/vacuum-packaging. III. BioTex chemists in collaboration with commercial facilities will perform studies to optimize conditions of radiation-based sterilization methods and to validate the efficacy of sterilization. IV. BioTex engineers will design and manufacture a device for sensor delivery, and complete study for sensor retrieval. V. BioTex scientists will collaborate with endocrinologist Dr. Eric Orzceck, MD, in order to guide us towards a feasible sensor design ready for human studies after completion of this project. We believe strongly that both the substantial amount of preliminary work and our team of experts will enable us to successfully accomplish the proposal Phase II objectives. The relevance of the glucose-sensing technology developed by BioTex, Inc. to public health lays in the need to find therapeutic means to minimize or even eliminate the devastating effects of diabetes to human health (especially juvenile Type I diabetes), like blindness, kidney failure, and increased mortality. If successful, the BioTex glucose- sensing technology will in conjunction with an insulin pump improve overall health level of people with diabetes by enabling autonomous blood-sugar control with minimal user intervention. The overall result will be a healthier life for people with diabetes and lower medical costs for diabetes care for the society.

描述(申请人提供)：迫切需要一种用于糖尿病治疗的长期体内血糖监测设备。据信，目前全世界有超过1亿人患有糖尿病，美国有近1800万人患有糖尿病。在美国，这种疾病及其相关并发症被列为第七大死亡原因。研究表明，如果血糖水平尽可能保持在接近正常水平(60-110 mg/dL)，即所谓的严格的血糖控制，这些长期并发症可以在糖尿病患者中降至最低。将连续的血糖监测读数集成到胰岛素泵自动控制算法中，可能会大大提高糖尿病患者胰岛素治疗的安全性和有效性。BioTex公司开发了一种最优的微创荧光亲和葡萄糖传感器的概念，这是目前在糖尿病研究和治疗中应用的最有前途的长期血糖传感技术之一。拟议研究的最终目标是推进我们的荧光传感器，为第二阶段完成后的初步人体试验做准备。为了实现这一具有挑战性的目标，我们将在第二阶段集中精力完成以下任务：I.BioTex的化学家和合作者Stephen Massia博士和Fred Clubb博士将设计、测试和优化合适的化学方案，以便在传感器外表面共价连接仿生层(S)，以提高生物兼容性，从而扩展大鼠体内传感器的功能。BioTex的化学家和工程师将进行研究，通过冷冻干燥/真空包装来优化传感器的预灭菌配方方案。BioTex化学家将与商业设施合作进行研究，以优化基于辐射的灭菌方法的条件，并验证灭菌效果。四、BioTex工程师将设计和制造传感器输送装置，并完成传感器回收的研究。V.BioTex的科学家将与内分泌学家Eric Orzceck博士合作，以指导我们设计出可行的传感器，以便在该项目完成后用于人体研究。我们坚信，大量的前期工作和我们的专家团队都将使我们能够成功地实现提案第二阶段的目标。BioTex，Inc.开发的葡萄糖传感技术与公共健康的相关性在于，需要找到治疗方法，将糖尿病对人类健康(特别是青少年I型糖尿病)的破坏性影响降至最低，甚至消除这些影响，如失明、肾功能衰竭和死亡率增加。如果成功，BioTex葡萄糖传感技术将与胰岛素泵相结合，通过在最少的用户干预下实现自主血糖控制，提高糖尿病患者的整体健康水平。总体结果将是糖尿病患者的生活更加健康，社会的糖尿病护理医疗成本将更低。